Drug intelligence / Profile preview

Apoxxim

Development stage: Preclinical
Lead developer: Riboxx Pharmaceuticals
Modality: RNA Therapeutics → Nucleic Acid Therapeutics

Overview

**Apoxxim** is a synthetic RNA-based Toll-like receptor 3 (TLR3) ligand developed by RIBOXX Pharmaceuticals for first-line immunotherapy of cancer. It activates the innate immune system by stimulating the TLR3 pathway on cancer cells, inducing apoptosis and eliminating tumors through immune-mediated mechanisms. The drug exhibits unique physicochemical and biological properties optimized for direct tumor cell killing and is available in GMP-grade formulations for clinical trials, with licensing agreements for development in specific cancer indications.[3][5][8]

Brand names: Apoxxim

Targets

TLR3 (Toll-like receptor 3)

Beyond the preview

Go deeper on Apoxxim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apoxxim.

Explore the full profile